$2.96
+0.21 (+7.64%)
Open$2.80
Previous Close$2.75
Day High$3.00
Day Low$2.77
52W High$16.43
52W Low$7.49
Volume—
Avg Volume65.7K
Market Cap98.80M
P/E Ratio45.14
EPS$0.30
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+412.8% upside
Current
$2.96
$2.96
Target
$15.18
$15.18
$12.50
$15.18 avg
$18.81
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.06M | 11.02M | 11.79M |
| Net Income | 2.28M | 2.12M | 2.45M |
| Profit Margin | 18.9% | 19.3% | 20.8% |
| EBITDA | 3.37M | 3.22M | 3.75M |
| Free Cash Flow | 1.70M | 2.02M | 1.47M |
| Rev Growth | +16.3% | -0.5% | +13.7% |
| Debt/Equity | 1.56 | 1.35 | 1.56 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |